MDCO-216

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameMDCO-216
Drug Alias NamerApoA-IMr-ApoA-I MilanorApoA-IM protein (dimer)MDCO-216ETC-216 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionLipid inhibitors
TargetsLipid
Therapy Area/IndicationsAcute Coronary Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaPoland +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Medicines Company
Active IndicationsN/A
Inactive IndicationsAcute Coronary Syndrome

Other Information

ATC CodeN/A
Related LinksN/A